THERE have been rumours circulating on social media that Yong Tai Bhd’s application for approval from National Pharmaceutical Regulatory Agency (NPRA) has been rejected.
Contrary to the rumours, the group is escalating the application process for its Phase III clinical trial tests as the company targets to obtain the compilation of Phase I and Phase II clinical trials data from its Chinese partner Shenzhen Kangtai Biological Products Co Ltd (SZKT) by next week.
Subsequently, submission would be made to the Health Ministry (MoH).
“We are still working closely with our Chinese partner to escalate the application process,” Yong Tai said in a statement.
“We urge all stakeholders to be patient and stop spreading untrue statement given the importance of the vaccine to help the nation achieve herd immunity.”
To recap, Yong Tai announced last week that the group and its Chinese partner SZKT have progressed into the clinical trials and commercialisation stage of their COVID-19 vaccine collaboration.
Through its subsidiary YTB Healthcare Sdn Bhd, Yong Tai has formalised their Phase III clinical and product procurement agreement which comes under the head of agreement framework purview that was signed in December last year.
Under the agreement, Yong Tai will bear the cost for the Phase III clinical trials in Malaysia while SZKT will bear all the costs for the supply of vaccine samples for the trials, including the cost of transporting the vaccine from China to Malaysia.
“We would like to reiterate its intention to help the nation achieve herd immunity as soon as possible,” Yong Tai added. – Feb 16, 2021
